
Pharma firms will present clinical trial results for the pipeline drugs they are pinning their 2016 hopes for success on, …

Eli Lilly has received FDA approval for its monoclonal antibody Portrazza, in combination with gemcitabine and cisplatin, for patients with …

Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …

Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …

Merck has entered a three-year agreement with Selvita to validate new therapeutic concepts in the field of oncology. The aim …

Leading figures from the pharma industry and cancer charities reacted with dismay to the recent cuts to the Cancer Drugs …

The US Defense Advanced Research Projects Agency (DARPA)’s $45 million ‘Big Mechanism’ initiative has an ambitious aim.It promises to “leapfrog …

AstraZeneca and Peregrine Pharmaceuticals will collaborate on a clinical trial to test two of the companies’ cancer treatments. The Phase …

Merck is teaming up with the University of Texas to evaluate Merck’s anti-PD-1 therapy, Keytruda, in combination with other treatmentsA team …

MedImmune has entered into a license agreement and collaboration with Inovio, a biotechnology company developing DNA-based immunotherapies for cancer and …

When we speak to Tom Lillie he’s brimming with excitement about the future for Amgen in oncology and the future …

AstraZeneca and Eli Lilly are teaming up to run a clinical trial of two of the companies’ anti-cancer drugs. The …
This year’s American Society of Clinical Oncology (ASCO) conference has a strong focus on immunotherapy, as pharma ramps up its …
Baxter is buying leukaemia treatment Oncaspar from Italian firm Sigma-Tau Finanziaria for $900 million as the US firm looks to …

Over $100 billion was spent on cancer medicines across the world last year as a new generation of drugs begins …